Stocktoria
Viatris Inc VTRS
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 1973-02-01
Viatris Inc financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $14.3B | $14.7B | $15.4B | $16.3B | $17.9B |
| Gross profit | $5.0B | $5.6B | $6.4B | $6.5B | $5.6B |
| R&D expense | — | — | — | — | $751.1M |
| SG&A expense | $3.8B | $4.1B | $4.1B | $4.2B | $4.5B |
| Operating income | -$2.7B | $10.1M | $766.2M | $1.6B | -$34.0M |
| Interest expense | $471.3M | $550.0M | $573.1M | $592.4M | $636.2M |
| Income tax | -$150.1M | $11.0M | $148.2M | $734.6M | $604.7M |
| Operating cash flow | $2.3B | $2.3B | $2.9B | $3.0B | $3.0B |
| Free cash flow | $1.9B | $2.0B | $2.5B | $2.6B | $2.6B |
| Cash & equivalents | $1.3B | $734.8M | $991.9M | $1.3B | $701.2M |
| Inventory | $4.0B | $3.9B | $3.5B | $3.5B | $4.0B |
| Total assets | $37.2B | $41.5B | $47.7B | $50.0B | $54.8B |
| Total liabilities | $22.5B | $22.9B | $27.2B | $28.9B | $34.4B |
| Shareholders' equity | $14.7B | $18.6B | $20.5B | $21.1B | $20.5B |
| EPS (diluted) | $-3.00 | $-0.53 | $0.05 | $1.71 | $-1.05 |
Source: SEC EDGAR filings · CIK 0001792044 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.